ATE318596T1 - Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii - Google Patents

Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii

Info

Publication number
ATE318596T1
ATE318596T1 AT02718005T AT02718005T ATE318596T1 AT E318596 T1 ATE318596 T1 AT E318596T1 AT 02718005 T AT02718005 T AT 02718005T AT 02718005 T AT02718005 T AT 02718005T AT E318596 T1 ATE318596 T1 AT E318596T1
Authority
AT
Austria
Prior art keywords
topoisomerase
succinimide
maleimide
formula
maleimide derivatives
Prior art date
Application number
AT02718005T
Other languages
English (en)
Inventor
Peter Buhl Jensen
Birgitte Sokilde
Elisabeth Vang Carstensen
Seppo W Langer
Andrew Creighton
Maxvell Sehested
Lars Hallund Jensen
Original Assignee
Topotarget As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget As filed Critical Topotarget As
Application granted granted Critical
Publication of ATE318596T1 publication Critical patent/ATE318596T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02718005T 2001-03-29 2002-03-27 Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii ATE318596T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100522 2001-03-29

Publications (1)

Publication Number Publication Date
ATE318596T1 true ATE318596T1 (de) 2006-03-15

Family

ID=8160403

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02718005T ATE318596T1 (de) 2001-03-29 2002-03-27 Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii

Country Status (5)

Country Link
EP (1) EP1373494B1 (de)
AT (1) ATE318596T1 (de)
AU (1) AU2002249103A1 (de)
DE (1) DE60209471D1 (de)
WO (1) WO2002078679A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291693B2 (en) 2001-06-25 2007-11-06 Massachusetts Institute Of Technology Bioerodible conducting materials
US7659278B2 (en) 2002-02-21 2010-02-09 Aprea Ab Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
WO2005004861A1 (en) * 2003-07-15 2005-01-20 Korea Research Institute Of Bioscience And Biotechnology A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
GB9605533D0 (en) * 1996-03-15 1996-05-15 Unilever Plc Modified aluminosilicate
DE19838506C2 (de) * 1998-05-04 2000-08-31 Asta Medica Ag Indolderivate und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
JP2002527419A (ja) * 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
JP4422916B2 (ja) * 1999-03-12 2010-03-03 トポターゲット・アクティーゼルスカブ アントラサイクリン類の事故的溢血の処置
JP5409981B2 (ja) * 2000-05-15 2014-02-05 セルジーン コーポレイション 癌治療用の組成物および方法

Also Published As

Publication number Publication date
EP1373494A2 (de) 2004-01-02
WO2002078679A2 (en) 2002-10-10
WO2002078679A3 (en) 2002-12-19
AU2002249103A1 (en) 2002-10-15
EP1373494B1 (de) 2006-03-01
DE60209471D1 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
EA200400480A1 (ru) N-замещённые производные пирролидина в качестве ингибиторов дипептидилпептидазы
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
NO20080150L (no) Inhibitorer av AKT-aktivitet
BR0114023A (pt) Derivados de imidazol como inibidores de quinase raf
BRPI0515500A (pt) derivados piridazina para inibição de estearoil-coa-desaturase
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
NO20061194L (no) Mitotiske kinesininbibitorer
ATE556048T1 (de) Prolinderivate und ihre verwendung als heilmittel
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
DE69922216D1 (de) Porphyrin derivate, ihre verwendung in der photodynamischen therapie und diese enthaltende medizinische geräte
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
HUP0300169A2 (en) Pyrrolidines which inhibit camp-specific pde, pharmaceutical compositions containing them and their use
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
ATE318596T1 (de) Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
DE60001586D1 (de) Diphenyl-piperidin derivate
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties